722,928 Shares in Allogene Therapeutics, Inc. $ALLO Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. acquired a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 722,928 shares of the company’s stock, valued at approximately $1,504,000.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Allogene Therapeutics by 9.2% in the third quarter. Vanguard Group Inc. now owns 9,020,770 shares of the company’s stock worth $11,186,000 after buying an additional 761,642 shares during the period. Primecap Management Co. CA grew its position in Allogene Therapeutics by 15.0% in the 4th quarter. Primecap Management Co. CA now owns 8,139,840 shares of the company’s stock valued at $11,152,000 after acquiring an additional 1,060,532 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Allogene Therapeutics by 177.9% in the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after purchasing an additional 3,747,397 shares during the period. Patient Square Capital LP lifted its position in shares of Allogene Therapeutics by 66.5% during the fourth quarter. Patient Square Capital LP now owns 4,963,756 shares of the company’s stock worth $6,800,000 after purchasing an additional 1,982,360 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Allogene Therapeutics by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 3,932,910 shares of the company’s stock worth $5,389,000 after purchasing an additional 99,025 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Trending Headlines about Allogene Therapeutics

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: The FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to cema-cel, potentially enabling more frequent regulatory interaction and an expedited review path. Allogene also plans to expand its ALPHA3 trial to approximately 100 sites by year-end, signaling an effort to accelerate enrollment and development. Allogene outlines plan for approximately 100 ALPHA3 sites and FDA grants RMAT and Fast Track
• Positive Sentiment: Allogene reported a second-quarter loss of $0.13 per share, better than the analyst consensus loss of $0.17, while revenue of $4.64 million exceeded expectations of essentially no revenue. The earnings beat may provide modest support for the shares, despite the company remaining unprofitable. Allogene second-quarter 2026 financial results and business update
• Neutral Sentiment: Management’s earnings call focused on advancing cema-cel and expanding the ALPHA3 study. These updates improve the program’s visibility, but the investment case remains dependent on clinical-trial execution, future data and regulatory decisions. Allogene Q2 2026 earnings call transcript
• Negative Sentiment: Allogene continues to report net losses and has no approved commercial product, leaving the company exposed to financing needs and the possibility of disappointing trial results. The FDA designations are not approvals and do not guarantee cema-cel’s success.

Analysts Set New Price Targets

ALLO has been the topic of a number of research analyst reports. JPMorgan Chase & Co. upgraded shares of Allogene Therapeutics from an “underweight” rating to a “neutral” rating in a report on Thursday, April 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Allogene Therapeutics in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.52.

Allogene Therapeutics Trading Down 2.4%

Shares of ALLO stock opened at $2.07 on Thursday. Allogene Therapeutics, Inc. has a twelve month low of $0.99 and a twelve month high of $4.46. The stock has a market capitalization of $714.46 million, a price-to-earnings ratio of -2.69 and a beta of 0.48. The stock has a fifty day simple moving average of $1.95 and a two-hundred day simple moving average of $2.12.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.04. The firm had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $0.00 million. Research analysts predict that Allogene Therapeutics, Inc. will post -0.7 EPS for the current fiscal year.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.